• Neuner SM, Heuer SE, Huentelman MJ, O'Connell KMS, Kaczorowski CC. Harnessing Genetic Complexity to Enhance Translatability of Alzheimer's Disease Mouse Models: A Path toward Precision Medicine. Neuron. 2019 Feb 6;101(3):399-411.

• Begley S. Scientists routinely cure brain disorders in mice but not us. A new study helps explain why, 2019.

• Hodge RD, Bakken TE, Miller JA, Smith KA, Barken ER, Graybuck LT, et al. Conserved cell types with divergent features in human versus mouse cortex.. Nature, 2019; 573(7772):61-68.

• Shansky RM. Are hormones a "female problem" for animal research?, 2019; 364(6443), 825-826

• Mullane K, Williams M. Preclinical Models of Alzheimer's Disease: Relevance and Translational Validity. Current Protocols in Pharmacology, 2019; 84, e57:1-28.

• Jankowky JL, Zheng H. Practical considerations for choosing a mouse model af Alzheimer's disease. Molecular Neurogeneration, 2018; Dec 22;12(1):89.

• Pound P, Pitskes-Hoitinga M. Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail. J Transl Med, 2018; Nov 7;16(1):304.

• Cross D. Rigor and Reproducibility in Federally-Funded Scientific Research: What are the Right Questions to Ask? Clarivate Analytics, 2017.

• Editorial Towards greater reproducibility. Nature, 2017;546(7656):8.

• Snyder H. Guidelines to improve animal study design and reproducibility for Alzheimer's disease and related dementias: For funders and researchers. Alzheimer's & Dementia, 2016; Nov;12(11):1177-1185.

• Perrin S. Preclinical research: Make mouse studies work. Nature. 2014;507(7493):423-5.

• Collins FS, Tabak LA. Policy: NIH plans to enhance reproducibility. Nature. 2014;505(7485):612-3.

• Egan KM, M. Two decades testing interventions in transgenic mouse models of Alzheimer's disease: designing and interpreting studies for clinical trial success. Clin Invest (Lond). 2014;4(8):693-704.

• Improving and Accelerating Therapeutic Development for Nervous System Disorders: Workshop Summary. Washington DC: 2014 by the National Academy of Sciences; 2014.

• Improving the Utility and Translation of Animal Models for Nervous System Disorders: Workshop Summary. Washington DC: National Academy of Sciences.; 2013.

• Bales KR. The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update. Expert Opin Drug Discov. 2012;7(4):281-97.

• Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. Osteoarthritis Cartilage. 2012;20(4):256-60.

• Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490(7419):187-91.

• Shineman DW, Basi GS, Bizon JL, Colton CA, Greenberg BD, Hollister BA, et al. Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies. Alzheimers Res Ther. 2011;3(5):28.

• van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, et al. Can animal models of disease reliably inform human studies? PLoS Med. 2010;7(3):e1000245.

• Sena ES, van der Worp HB, Bath PM, Howells DW, Macleod MR. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol. 2010;8(3):e1000344.

• Zahs KR, Ashe KH. 'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci. 2010;33(8):381-9.

• Benedikz E, Kloskowska E, Winblad B. The rat as an animal model of Alzheimer's disease. J Cell Mol Med. 2009;13(6):1034-42.

• Markou A, Chiamulera C, Geyer MA, Tricklebank M, Steckler T. Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology. 2009;34(1):74-89.

• Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler. 2008;9(1):4-15.